Finnish universities are exploring wireless power transmission through various methods, but claims of a significant breakthrough are exaggerated. The most notable experiment, involving ultrasonic spark guidance, does not enable usable power transfer. Aalto University's wireless charging shows promise, yet overall, the research is still nascent and limited to niche applications.
Finnish universities are exploring wireless power transmission through various methods, but claims of a significant breakthrough are exaggerated. The most notable experiment, involving ultrasonic spark guidance, does not enable usable power transfer. Aalto University's wireless charging shows promise, yet overall, the research is still nascent and limited to niche applications.
Japanese researchers initiated Phase I human trials of a tooth-regrowing drug, TRG-035, at Kyoto University Hospital in October 2024, targeting USAG-1 protein inhibition. With 30 participants, the trials aim for commercial readiness by 2030. While promising, experts caution that significant challenges remain before widespread availability.
KEY POINTS:
• The United States officially withdrew from the World Health Organization on January 22, 2026, one year after President Trump signed Executive Order...
Alphabet has reached a $4 trillion market valuation, joining Nvidia, Microsoft, and Apple. The company's stock rose significantly after Apple announced a partnership to utilize Google's Gemini AI models for its services. Alphabet's strong performance has been bolstered by advancements in AI technology and growth in its cloud business, surpassing Apple in market capitalization.
Finnish universities are exploring wireless power transmission through various methods, but claims of a significant breakthrough are exaggerated. The most notable experiment, involving ultrasonic spark guidance, does not enable usable power transfer. Aalto University's wireless charging shows promise, yet overall, the research is still nascent and limited to niche applications.
Japanese researchers initiated Phase I human trials of a tooth-regrowing drug, TRG-035, at Kyoto University Hospital in October 2024, targeting USAG-1 protein inhibition. With 30 participants, the trials aim for commercial readiness by 2030. While promising, experts caution that significant challenges remain before widespread availability.
KEY POINTS:
• The United States officially withdrew from the World Health Organization on January 22, 2026, one year after President Trump signed Executive Order...